« Back
Home /
NX-1607

NX-1607

Item no.	HY-141432-1mg
Manufacturer	MedChem Express
CASRN	2573775-59-2
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.87
Citations	[1]Arthur T. Sands, et al. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof. WO2020264398A1.
Smiles	CN1C([C@@]2(C3=CC(N4CC5=C(C(F)(F)F)C=C(CN6C[C@H](CCC6)C)C=C5C4=O)=CC=C3)C[C@H](C2)C)=NN=C1
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	Cbl-b-IN-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	E1/E2/E3 Enzyme
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	537.62
Product Description	NX-1607 (Compound 23) is an inhibitor of Cbl-b, an E3 enzyme in the ubiquitin-proteasome pathway, with an IC50 value of less than 1 nM. NX-1607 can be used in cancer research[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-141432-1mg-safety-datasheet.pdf